Filter
827
Text search:
dosing
Featured
116
224
Language
Document type
465
181
93
29
21
16
12
4
2
1
1
1
1
Countries / Regions
46
35
27
23
19
17
15
11
10
10
9
9
9
8
8
8
8
7
7
6
6
6
5
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
266
169
49
28
26
19
3
1
Toolboxes
114
87
66
42
36
32
22
19
14
14
9
8
7
6
6
2
2
2
1
1
Для создания этого отчета MSF исследовала программы и практику лечения лекарственно-чувствительного и лекарственно-устойчивого туберкулеза в восьмистранах с высо
...
Исследование этого года основано на предыдущем отчете. В нем отслеживается утверждение последних стратегий, руководств и методов в пяти сферах: диагностика и иссл
...
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Venturini et al. BMC Infectious Diseases 2014, 14(Suppl 1):S5 http://www.biomedcentral.com/1471-2334/14/S1/S5
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
The toolkit's purpose is to:
improve the primary health care response for older persons.
sensitize and educate primary health care workers about the specific needs of their older clients.
provide primary care health workers with a set of tools/instruments to assess older people's hea
...
In many low- and middle-income countries, there is a wide gap between evidencebased recommendations and current practice. Treatment of major CVD risk factors remains suboptimal, and only a minority of patients who are treated reach their target levels for blood pressure, blood sugar and blood choles
...
Accessed: 30.10.2019
MSF International AIDS Working Group
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es
...
Accessed February 6, 2020
Consolidated Guidelines
Geneva, 2016
The End TB Strategy